The CDC issued an alert
The CDC maintains that the benefits of taking Paxlovid far outweigh the risks. “I have never seen rebound with the use of ivermectin, hydroxychloroquine or the combination which is what I most frequently use,” said Dr. Pierre Kory, Chief Medical Officer of the FLCCC. “Further, those two drugs are magnitudes safer than Paxlovid. Ivermectin has many mechanisms of action, one of which is the same as Paxlovid, and I question any pharmaceutical company sponsored trial. I would never use a novel drug based on their data.”
Dr. Paul Marik noted that a recent study from Israel demonstrated that Paxlovid was completely ineffective in high-risk vaccinated patients between the ages of 40-64 years with confirmed SARS-CoV-2 infection during the omicron surge. “Pfizer likely knew that Paxlovid did not work in the vaccinated and removed them from the EPIC-SR trial,” said Dr. Marik.
“The high failure rate in the vaccinated and the high relapse rates are likely because Paxlovid is an ineffective drug for the treatment of Covid-19. We are unaware of any reports of rebound infections in patients treated with either ivermectin or hydroxychloroquine.”
1. Arbel R, Sagy YW, Hoshen M et al. Oral nirmatrelvir and severe COVID-19 outcomes during the Omicron surge. Research Square 2022.